Stier Matthew W, Konda Vani J, Hart John, Waxman Irving
Matthew W Stier, Department of Internal Medicine, The University of Chicago Medicine, Chicago, IL 60637, United States.
World J Gastroenterol. 2016 May 7;22(17):4297-306. doi: 10.3748/wjg.v22.i17.4297.
Barrett's esophagus (BE) is a pre-malignant condition affecting up to 15% of patients with gastroesophageal reflux disease. Neoplastic Barrett's mucosa is defined as harboring high grade dysplasia or intra-mucosal cancer, and carries a high risk of progression to esophageal adenocarcinoma. The rising incidence of Barrett's lesions along with the high morbidity of surgical approaches has led to the development of numerous validated endoscopic techniques capable of eradicating neoplastic mucosa in a minimally invasive manner. While there has been widespread adoption of these techniques, less is known about optimal surveillance intervals in the post-therapy period. This is due in part to limitations in current surveillance methods, questions about durability of treatment response and the risk of subendothelial progression. As we are now able to achieve organ sparing eradication of superficial neoplasia in BE, we need to also then focus our attention on how best to manage these patients after eradication is achieved. Implementing optimal surveillance practices requires additional understanding of the biology of the disease, appreciation of the limits of current tools and treatments, and exploration of the role of adjunctive technologies. The aim of this article is to provide a comprehensive review of current literature surrounding post-ablation surveillance in neoplastic BE.
巴雷特食管(BE)是一种癌前病变,影响高达15%的胃食管反流病患者。肿瘤性巴雷特黏膜被定义为存在高级别异型增生或黏膜内癌,并且进展为食管腺癌的风险很高。巴雷特病变的发病率不断上升,同时手术方法的高发病率促使人们开发了许多经过验证的内镜技术,这些技术能够以微创方式根除肿瘤性黏膜。虽然这些技术已被广泛采用,但对于治疗后最佳监测间隔的了解却较少。部分原因在于当前监测方法的局限性、关于治疗反应持久性的问题以及黏膜下进展的风险。由于我们现在能够实现对BE浅表肿瘤的保留器官根除,因此我们还需要将注意力集中在根除实现后如何最好地管理这些患者。实施最佳监测实践需要对疾病生物学有更多了解,认识当前工具和治疗的局限性,并探索辅助技术的作用。本文的目的是对当前围绕肿瘤性BE消融后监测的文献进行全面综述。